BCAX - CIK 0002023658
The table below shows Bicara Therapeutics Inc.'s cash flow statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating cash flow | -$106.83M | -$74.75M | -$45.63M |
| Capital expenditure | $280.00K | $71.00K | $586.00K |
| Investing cash flow | -$318.45M | -$9.00K | -$586.00K |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $32.26M | $334.03M | $272.50M |
Bicara Therapeutics Inc. reported operating cash flow of -$106.83M for fiscal year 2025. That is down 42.9% from -$74.75M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.